Profile data is unavailable for this security.
About the company
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
- Revenue in USD (TTM)0.00
- Net income in USD-7.07m
- Incorporated2023
- Employees9.00
- LocationMymd Pharmaceuticals Inc855 N. Wolfe Street, Suite 601BALTIMORE 21205United StatesUSA
- Websitehttps://www.mymd.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scorpius Holdings Inc | 2.23m | -46.05m | 6.70m | 77.00 | -- | 0.1336 | -- | 3.01 | -1.78 | -2.00 | 0.0859 | 1.39 | 0.0234 | -- | 0.6762 | 28,918.57 | -50.05 | -38.42 | -61.25 | -42.06 | 29.10 | -- | -2,136.28 | -703.02 | -- | -- | 0.2305 | -- | 202.12 | 33.24 | -23.85 | -- | 218.50 | -- |
Cannabis Bioscience Internatnl Hlgs Inc | 56.94m | 6.94m | 6.75m | 389.00 | 0.0012 | 0.0001 | 0.7315 | 0.1185 | 0.5328 | 0.5328 | 4.29 | 4.92 | 0.5917 | 62.81 | 1.45 | 146,384.30 | 7.83 | -- | 11.73 | -- | 31.96 | -- | 13.24 | -- | 0.6856 | 50.75 | 0.0631 | -- | 12.79 | -- | 177.84 | -- | -- | -- |
Adial Pharmaceuticals Inc | 0.00 | -7.00m | 6.89m | 4.00 | -- | 0.6925 | -- | -- | -5.83 | -4.17 | 0.00 | 2.45 | 0.00 | -- | -- | 0.00 | -133.76 | -182.35 | -174.49 | -235.45 | -- | -- | -- | -- | -- | -55.50 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
Theriva Biologics Inc | 0.00 | -18.35m | 6.91m | 21.00 | -- | 0.187 | -- | -- | -1.15 | -1.15 | 0.00 | 2.31 | 0.00 | -- | -- | 0.00 | -28.88 | -36.95 | -32.40 | -40.16 | -- | -- | -- | -- | -- | -- | 0.0056 | -- | -- | -- | 8.37 | -- | 95.91 | -- |
AiXin Life International Inc | 4.09m | -2.09m | 7.00m | 207.00 | -- | -- | -- | 1.71 | -0.0836 | -0.0836 | 0.1636 | -0.0765 | 0.8268 | 5.43 | 10.02 | 19,757.49 | -42.27 | -16.93 | -- | -34.54 | 16.25 | 48.13 | -51.12 | -36.96 | 0.1515 | -- | -- | -- | 51.00 | 58.08 | 67.18 | -- | 194.59 | -- |
Calidi Biotherapeutics Inc | 0.00 | -28.74m | 7.04m | 38.00 | -- | -- | -- | -- | -0.6324 | -0.6324 | 0.00 | -0.0241 | 0.00 | -- | -- | 0.00 | -284.51 | -- | -- | -- | -- | -- | -- | -- | -- | -25.25 | 1.25 | -- | -89.98 | -- | -132.57 | -- | -- | -- |
Enveric Biosciences Inc | 0.00 | -17.46m | 7.15m | 7.00 | -- | 1.37 | -- | -- | -8.15 | -8.15 | 0.00 | 0.7142 | 0.00 | -- | -- | 0.00 | -144.99 | -104.94 | -207.98 | -156.88 | -- | -- | -- | -243.54 | -- | -- | 0.00 | -- | -- | -- | 7.14 | -- | -- | -- |
Pulmatrix Inc | 7.30m | -14.12m | 7.16m | 22.00 | -- | 0.3978 | -- | 0.9809 | -3.87 | -3.87 | 2.00 | 4.93 | 0.1948 | -- | 6.56 | 331,727.30 | -37.70 | -46.91 | -42.80 | -58.12 | -- | -- | -193.49 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
Kazia Therapeutics Ltd (ADR) | 14.91k | -13.52m | 7.17m | 12.00 | -- | 0.7789 | -- | 480.98 | -0.8203 | -0.8203 | 0.0008 | 0.3492 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
CV Sciences Inc | 16.00m | 3.10m | 7.18m | 42.00 | 2.13 | 2.45 | 2.15 | 0.4488 | 0.0206 | 0.0206 | 0.104 | 0.018 | 1.46 | 1.46 | 26.74 | 381,047.60 | 28.28 | -43.42 | 247.47 | -77.75 | 44.27 | 51.81 | 19.38 | -45.68 | 0.3733 | 13.68 | 0.0805 | -- | -1.24 | -19.80 | 133.96 | -20.87 | -- | -- |
MyMD Pharmaceuticals Inc | 0.00 | -7.07m | 7.18m | 9.00 | -- | 0.3397 | -- | -- | -5.53 | -5.53 | 0.00 | 10.28 | 0.00 | -- | -- | 0.00 | -25.59 | -76.20 | -31.13 | -84.38 | -- | 7.64 | -- | -4,290.96 | -- | -- | 0.00 | -- | -- | -- | 49.15 | -- | -- | -- |
Pasithea Therapeutics Corp | 0.00 | -15.51m | 7.21m | 8.00 | -- | 0.308 | -- | -- | -12.83 | -13.18 | 0.00 | 22.46 | 0.00 | -- | -- | 0.00 | -43.50 | -- | -46.44 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.23 | -- | -- | -- |
Shuttle Pharmaceuticals Holdings Inc | 0.00 | -6.59m | 7.22m | 8.00 | -- | 1.70 | -- | -- | -0.441 | -0.441 | 0.00 | 0.2524 | 0.00 | -- | -- | 0.00 | -90.28 | -- | -104.75 | -- | -- | -- | -- | -- | -- | -49.56 | 0.1527 | -- | -- | -- | -112.71 | -- | -- | -- |
Intelligent Bio Solutions Inc | 2.46m | -13.40m | 7.28m | 17.00 | -- | 0.096 | -- | 2.96 | -131.37 | -131.37 | 20.91 | 26.67 | 0.1831 | 2.41 | 9.09 | 144,726.50 | -99.96 | -80.65 | -157.15 | -224.84 | 20.90 | -- | -545.95 | -948.54 | 0.3864 | -- | 0.1602 | -- | 187.51 | 367.97 | -28.00 | -- | -- | -- |
Tenax Therapeutics Inc | 0.00 | -7.71m | 7.52m | 5.00 | -- | 0.1414 | -- | -- | -33.51 | -33.51 | 0.00 | 27.15 | 0.00 | -- | -- | 0.00 | -102.20 | -199.16 | -159.72 | -285.64 | -- | -- | -- | -- | -- | -82.13 | 0.0583 | -- | -- | -- | 30.21 | -- | -- | -- |
Trevena Inc | 3.13m | -40.29m | 7.56m | 23.00 | -- | -- | -- | 2.42 | -3.16 | -3.16 | 0.2611 | -0.4429 | 0.07 | 3.69 | -- | 135,869.60 | -90.25 | -55.93 | -110.38 | -66.35 | 46.56 | -- | -1,289.25 | -3,134.41 | 4.66 | -15.43 | 1.33 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
Holder | Shares | % Held |
---|---|---|
Global X Management Co. LLCas of 31 Mar 2024 | 875.93k | 40.60% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 48.30k | 2.24% |
Geode Capital Management LLCas of 31 Dec 2023 | 9.71k | 0.45% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 6.62k | 0.31% |
Iroquois Capital Management LLCas of 31 Dec 2023 | 6.25k | 0.29% |
Cambria Investment Management LPas of 31 Dec 2023 | 5.72k | 0.27% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 4.01k | 0.19% |
NWAM LLCas of 31 Dec 2023 | 2.27k | 0.11% |
Millennium Management LLCas of 31 Dec 2023 | 2.07k | 0.10% |
Susquehanna Financial Group LLLPas of 31 Dec 2023 | 2.01k | 0.09% |